Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24953182 | 0.84 | TTR (0.67) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15828247 | 0.82 | TTR (0.71) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20145409 | 0.78 | TTR (0.69) | TTRALBSMN1; SMN2MEN1KMT2A | |
| Acoramidis SCHEMBL29350324 | 0.78 | TTR (1.00) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24953188 | 0.78 | TTR (0.83) | TTRALBSMN1; SMN2MEN1KMT2A | |
| Acoramidis SCHEMBL15816954 | 0.78 | TTR (1.00) | TTRALBSMN1; SMN2MEN1KMT2A | |
| Acoramidis SCHEMBL29390976 | 0.77 | TTR (0.98) | TTRALBSMN1; SMN2MEN1KMT2A | |
| Acoramidis SCHEMBL20475239 | 0.77 | TTR (0.98) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15816998 | 0.77 | TTR (0.81) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15158388 | 0.76 | TTR (1.00) | TTRALBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221508-A1 | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180221503-A1 | COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221503-A1 | COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES | CD47, FCGR3B, FCGR1A | TTR 988/4885ALB 211/4885SMN1; SMN2 2687/4885 |
| US-20180221508-A1 | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION | CD47, ICOS, PBK | TTR 520/4885ALB 1556/4885SMN1; SMN2 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.